Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors

NCT05286801 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

86

Enrollment

NIH

Sponsor class

Conditions

Atypical Teratoid/Rhabdoid Tumor
Epithelioid Sarcoma
Kidney Medullary Carcinoma
Malignant Solid Neoplasm
Poorly Differentiated Chordoma
Recurrent Atypical Teratoid/Rhabdoid Tumor
Recurrent Chordoma
Recurrent Epithelioid Sarcoma
Recurrent Kidney Medullary Carcinoma
Recurrent Malignant Solid Neoplasm
Recurrent Rhabdoid Tumor
Refractory Atypical Teratoid/Rhabdoid Tumor
Refractory Chordoma
Refractory Epithelioid Sarcoma
Refractory Kidney Medullary Carcinoma
Refractory Malignant Solid Neoplasm
Refractory Rhabdoid Tumor
Rhabdoid Tumor

Interventions

BIOLOGICAL: Atezolizumab
PROCEDURE: Biospecimen Collection
PROCEDURE: Computed Tomography
PROCEDURE: Echocardiography Test
OTHER: Fludeoxyglucose F-18
PROCEDURE: Magnetic Resonance Imaging
PROCEDURE: Positron Emission Tomography
BIOLOGICAL: Tiragolumab
PROCEDURE: X-Ray Imaging

Sponsor

National Cancer Institute (NCI)